2023 - 01 - 30

Stemline Therapeutics, a subsidiary of Menarini Group, Receives U.S. FDA Approval for ORSERDU™ (elacestrant) as the First and Only Treatment Specifically Indicated for Patients with ESR1 Mutations

2023 - 02 - 08

Menarini Group are with the Turkish and Syrian populations

2023 - 02 - 21

Karyopharm and Menarini Group Receive Full Marketing Authorization from the UK Medicines & Healthcare Products Regulatory Agency for NEXPOVIO^® (selinexor)

2023 - 03 - 14

Neoplasia a Cellule Dendritiche Plasmacitoidi Blastiche: Aifa approva Tagraxofusp prima e unica terapia contro tumore del sangue raro e aggressivo

2023 - 04 - 13

The Dates of the XXVII Edition of the International Fair Play Menarini Awards

2023 - 04 - 19

Menarini announces an exclusive distribution agreement for Boditech’s AFIAS-10 system

2023 - 05 - 02

The doors of Europe open wide for the Volpi Rosse Menarini

2023 - 05 - 04

Birth rate emergency, younger generations say: “It’s not just an issue of economic stability”

2023 - 05 - 09

Menarini Group Announces New Data on Elacestrant at 2023 ESMO Breast Cancer Congress and 2023 ASCO Annual Meeting

2023 - 05 - 14

Botticelli, the inquietude and the beauty

2023 - 05 - 26

Menarini Group Shares New Analysis from EMERALD Clinical Study of ORSERDU^® (Elacestrant) in Metastatic Breast Cancer at ASCO 2023

2023 - 06 - 08

Menarini Group Shares NEXPOVIO® (selinexor) Subgroup Data from BOSTON trial at the European Hematology Association Congress, Highlighting Clinical Potential in Relapsed/Refractory Multiple Myeloma

2023 - 06 - 19

Fair Play Menarini International Awards announces the winners of the XXVII edition at CONI

2023 - 06 - 27

Fair Play Menarini International Awards, young swimmer Gianluca Gensini wins the ‘Fiamme Gialle’ special “Studio and Sport” award

2023 - 07 - 02

Fair Play Menarini International Awards, the 2023 edition starts with the talk show “The Champions tell their Stories” in Piazza della Signoria, Florence

2023 - 07 - 03

Great news at the Fair Play Menarini International Awards, tennis player Francesca Schiavone among the winners of the 2023 edition

2023 - 07 - 04

Fair Play Menarini International Awards, excitement is building for the awards ceremony after the “The Champions Tell their Stories”

2023 - 07 - 05

Fair Play Menarini International Awards, the champions of Fair Play cast their spell on the audience in Fiesole

2023 - 07 - 21

Menarini Group Receives Positive CHMP Opinion Recommending EC Approval of ORSERDU® (Elacestrant) for the Treatment of Patients with ER+, HER2- Locally Advanced or Metastatic Breast Cancer

2023 - 08 - 30

The Menarini Group Announces ELZONRIS® (Tagraxofusp) Designated as an Orphan Drug for BPDCN by Japanese Ministry of Health, Labor and Welfare

2023 - 09 - 20

European Commission Approves Menarini Group’s ORSERDU^® (Elacestrant) for the Treatment of Patients with ER+, HER2- Locally Advanced or Metastatic Breast Cancer with an Activating ESR1 Mutation

2023 - 10 - 18

The 2023 Season gets underway for the Volpi Rosse Menarini Wheelchair Basketball Team

2023 - 10 - 19

European Organisation for Research and Treatment of Cancer & the Menarini Group Launch New Clinical Trial in Early-Stage Breast Cancer

2023 - 11 - 07

Menarini Group and SciClone Pharmaceuticals Announce Exclusive Sub-Licensing Collaboration to Develop and Commercialize ORSERDU® (Elacestrant) in China to Address Advanced or Metastatic Breast Cancer

2023 - 11 - 20

Menarini Group Announces New Data on ORSERDU® (elacestrant) at the 2023 San Antonio Breast Cancer Symposium and on ELZONRIS® (tagraxofusp-erzs) at the 65th American Society of Hematology

2023 - 12 - 08

Menarini Group Presents New Progression-Free Survival Data from EMERALD Clinical Study of ORSERDU® (Elacestrant) in Clinically Relevant Subgroups of Patients with ER+, HER2- Metastatic Breast Cancer

2023 - 12 - 11

Menarini Group Presented Initial Safety and Efficacy Data from Phase 1b/2 ELEVATE and ELECTRA Combination Studies of ORSERDU® (Elacestrant) in Patients with ER+, HER2- Metastatic Breast Cancer (mBC)